Coronavirus (COVID-19)
Learn more
May 09, 2017
Sponsor: Southwest Oncology Group
Number: SWOG-1400
Eligible patients who enroll in the study will be randomly assigned (by chance) to this screening and multi-sub-study phase II/III trial (Phase II: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety. Phase III: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely) will establish a method for genomic screening (a type of medical test that identifies changes in chromosomes, genes, or proteins) of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid "Master Protocol" (S1400). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned. This study is used to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes a "non-match" sub-study which will include all screened patients not eligible for any of the biomarker-driven sub-studies. This sub-study will compare a non-match therapy to standard of care also with the goal of approval.
Who’s eligible:
Available at: The Hospital of Central Connecticut, Backus Hospital, MidState Medical Center, and Hartford Hospital.
Referral Line: 860.972.4700
Get the latest healthcare news directly in your inbox.
To receive our health news text alerts / text StartHere to 85209